atenolol has been researched along with Cirrhosis in 11 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure." | 9.12 | Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. ( Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007) |
| " We compared the effects of nebivolol and atenolol, a first generation β1-selective blocker, on left ventricular hypertrophy, fibrosis, and function and microRNA expression in a rodent model of hypertension." | 7.79 | Nebivolol induces distinct changes in profibrosis microRNA expression compared with atenolol, in salt-sensitive hypertensive rats. ( Birnbaum, Y; Castillo, AC; Chen, X; Ling, S; Long, B; Perez-Polo, JR; Qian, J; Thomas, B; Ye, H; Ye, Y, 2013) |
| "In hypertensive left ventricular hypertrophy (LVH), myocardial texture is altered by a disproportionate increase in fibrosis, but there is insufficient clinical evidence whether antihypertensive therapy or individual agents can induce regression of myocardial fibrosis." | 6.71 | Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. ( Ciulla, MM; Dahlöf, B; Dìez, J; Esposito, A; Gilles, L; López, B; Magrini, F; Nicholls, MG; Paliotti, R; Smith, RD; Zanchetti, A, 2004) |
| "In 204 patients with hypertension and left ventricular (LV) hypertrophy we measured serum concentration of carboxy-terminal telopeptide of type I procollagen (ICTP), carboxy-terminal propeptide of type I procollagen (PICP), amino-terminal propeptide of type III procollagen (PIIINP), amino-terminal propeptide of type I procollagen (PINP) and LV mass by echocardiography at baseline and annually during 4 years of losartan- or atenolol-based antihypertensive treatment; 185 patients completed the study." | 5.12 | Does long-term losartan- vs atenolol-based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. ( Bang, LE; Christensen, MK; Devereux, RB; Fossum, E; Hildebrandt, P; Ibsen, H; Kjeldsen, SE; Olsen, MH; Rokkedal, J; Tuxen, C; Wachtell, K; Wiinberg, N, 2006) |
| "To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure." | 5.12 | Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. ( Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007) |
| " We compared the effects of nebivolol and atenolol, a first generation β1-selective blocker, on left ventricular hypertrophy, fibrosis, and function and microRNA expression in a rodent model of hypertension." | 3.79 | Nebivolol induces distinct changes in profibrosis microRNA expression compared with atenolol, in salt-sensitive hypertensive rats. ( Birnbaum, Y; Castillo, AC; Chen, X; Ling, S; Long, B; Perez-Polo, JR; Qian, J; Thomas, B; Ye, H; Ye, Y, 2013) |
| "Atenolol, a first-generation β-blocker, effectively reduces blood pressure, although its use in metabolic syndrome remains controversial." | 3.77 | Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats. ( Angerosa, M; Cao, G; Dominici, FP; Giani, JF; Muñoz, MC; Toblli, JE, 2011) |
| "The effects of propranolol and atenolol were investigated on arterial hypertension, cardiomyocyte hypertrophy, and ventricular ischaemic lesions induced by an 8-week treatment with the nitric oxide synthase inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME; 20 mg/rat per day) in Wistar rats." | 3.71 | Attenuation of hypertension, cardiomyocyte hypertrophy, and myocardial fibrosis by beta-adrenoceptor blockers in rats under long-term blockade of nitric oxide synthesis. ( Antunes, E; de Azevedo, AP; De Luca, IM; De Nucci, G; De Oliveira, CF; Pacca, SR, 2002) |
| "In hypertensive left ventricular hypertrophy (LVH), myocardial texture is altered by a disproportionate increase in fibrosis, but there is insufficient clinical evidence whether antihypertensive therapy or individual agents can induce regression of myocardial fibrosis." | 2.71 | Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. ( Ciulla, MM; Dahlöf, B; Dìez, J; Esposito, A; Gilles, L; López, B; Magrini, F; Nicholls, MG; Paliotti, R; Smith, RD; Zanchetti, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 7 (63.64) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Voets, M | 1 |
| Antes, I | 1 |
| Scherer, C | 1 |
| Müller-Vieira, U | 1 |
| Biemel, K | 1 |
| Marchais-Oberwinkler, S | 1 |
| Hartmann, RW | 1 |
| Ye, H | 1 |
| Ling, S | 1 |
| Castillo, AC | 1 |
| Thomas, B | 1 |
| Long, B | 1 |
| Qian, J | 1 |
| Perez-Polo, JR | 1 |
| Ye, Y | 1 |
| Chen, X | 1 |
| Birnbaum, Y | 1 |
| Hikiji, W | 1 |
| Kudo, K | 1 |
| Nishida, N | 1 |
| Ishida, T | 1 |
| Usumoto, Y | 1 |
| Tsuji, A | 1 |
| Ikeda, N | 1 |
| Toblli, JE | 1 |
| Cao, G | 1 |
| Giani, JF | 1 |
| Muñoz, MC | 1 |
| Angerosa, M | 1 |
| Dominici, FP | 1 |
| Villa, L | 1 |
| Boor, P | 1 |
| Konieczny, A | 1 |
| Kunter, U | 1 |
| van Roeyen, CR | 1 |
| Denecke, B | 1 |
| Gan, L | 1 |
| Neusser, MA | 1 |
| Cohen, CD | 1 |
| Eitner, F | 1 |
| Scholl, T | 1 |
| Ostendorf, T | 1 |
| Floege, J | 1 |
| Ciulla, MM | 1 |
| Paliotti, R | 1 |
| Esposito, A | 1 |
| Dìez, J | 2 |
| López, B | 2 |
| Dahlöf, B | 1 |
| Nicholls, MG | 1 |
| Smith, RD | 1 |
| Gilles, L | 1 |
| Magrini, F | 1 |
| Zanchetti, A | 1 |
| Christensen, MK | 1 |
| Olsen, MH | 1 |
| Wachtell, K | 1 |
| Tuxen, C | 1 |
| Fossum, E | 1 |
| Bang, LE | 1 |
| Wiinberg, N | 1 |
| Devereux, RB | 1 |
| Kjeldsen, SE | 1 |
| Hildebrandt, P | 1 |
| Rokkedal, J | 1 |
| Ibsen, H | 1 |
| Cavallari, LH | 1 |
| Momary, KM | 1 |
| Groo, VL | 1 |
| Viana, MA | 1 |
| Camp, JR | 1 |
| Stamos, TD | 1 |
| Müller-Brunotte, R | 1 |
| Kahan, T | 1 |
| Edner, M | 1 |
| González, A | 1 |
| Malmqvist, K | 1 |
| Agarwal, DK | 1 |
| Barthwal, SP | 1 |
| Agarwal, R | 1 |
| Tandon, S | 1 |
| Agarwal, RL | 1 |
| Pacca, SR | 1 |
| de Azevedo, AP | 1 |
| De Oliveira, CF | 1 |
| De Luca, IM | 1 |
| De Nucci, G | 1 |
| Antunes, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Randomized, Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy[NCT00389168] | Phase 2/Phase 3 | 115 participants (Actual) | Interventional | 1995-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Difference in Diastolic Blood Pressure. Repeated measures multivariable analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Atenolol | -16.3 |
| Irbesartan | -18.8 |
Changes in common carotid artery intima-media thickness, assessed by ultrasonography. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | mm (Mean) |
|---|---|
| Atenolol | 0.03 |
| Irbesartan | -0.01 |
Safety was assessed by non-directed questions, and all observed and volunteered adverse events were recorded at each study visit. Serious adverse events were defined by, and reported according to the regulations of good clinical practice (GCP). none were considered related to the study medication. (NCT00389168)
Timeframe: Treatment period was baseline to 48 weeks
| Intervention | Participants (Number) |
|---|---|
| Atenolol | 5 |
| Irbesartan | 5 |
Repeated measures multivariate analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks. Data are presented as left ventricular mass in gram (g) indexed for body mass index (in m^2). (NCT00389168)
Timeframe: Baseline and 48 weeks
| Intervention | g/m^2 (Mean) | ||
|---|---|---|---|
| 12 weeks | 24 weeks | 48 weeks | |
| Atenolol | -1 | -6 | -14 |
| Irbesartan | -9 | -14 | -26 |
Venous plasma concentrations of angiotensin II were measured in order to study the possible associations between the activity of the renin-angiotensin-aldosteone system and changes in left ventricular mass. Further analyses of other components of the renin-angiotensin-aldosterone system and of other hormonal system (e.g. the sympathetic nervous system) have also been performed and published. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Data were log-transformed to avoid skewness before statistical evaluation. However, tabular data are given as mean values with 95% confidence to improve readability. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | pmol/L (Mean) | ||
|---|---|---|---|
| Weel 12 | Week 24 | Week 48 | |
| Atenolol | -1.0 | -0.8 | -0.2 |
| Irbesartan | 3.0 | 3.3 | 10.0 |
Changes in left ventricular diastolic function from baseline to week 48 will be evaluated as the difference in E/A ratio. Conventional pulsed wave Doppler echocardiography was used for recordings of mitral inflow in. The peak of early (E) and late (A) mitral flow velocities were measured, and the E/A-ratio was calculated. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Some echocardiographic recordings at some time point may be of insufficient quality or missing, and the number of observations may not always correspond to the total number of participants at all time points. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | ratio (Mean) | ||
|---|---|---|---|
| Week 12 | Week 24 | Week 48 | |
| Atenolol | 0.18 | 0.16 | 0.13 |
| Irbesartan | 0.10 | 0.04 | 0.10 |
4 trials available for atenolol and Cirrhosis
7 other studies available for atenolol and Cirrhosis
| Article | Year |
|---|---|
Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Topics: Animals; Binding Sites; Cell Line; Cell Membrane Permeability; Cricetinae; Cricetulus; Cytochrome P- | 2006 |
Nebivolol induces distinct changes in profibrosis microRNA expression compared with atenolol, in salt-sensitive hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Atenolol; Benzopyrans; Blood Pressure | 2013 |
Acute fatal poisoning with pilsicainide and atenolol.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Chromatography, High Pressure Liquid; Depression; Fema | 2008 |
Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats.
Topics: Adrenergic beta-1 Receptor Antagonists; Animals; Atenolol; Benzopyrans; Blood Pressure; Diabetes Mel | 2011 |
Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; | 2013 |
Peritoneal fibrosis--an expression of atenolol toxicity.
Topics: Atenolol; Fibrosis; Humans; Hypertension; Male; Middle Aged; Peritoneal Diseases; Peritoneum; Tissue | 1994 |
Attenuation of hypertension, cardiomyocyte hypertrophy, and myocardial fibrosis by beta-adrenoceptor blockers in rats under long-term blockade of nitric oxide synthesis.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressu | 2002 |